Comparative study of clinical grade human tolerogenic dendritic cells

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Naranjo Gomez M ^a   Raich Regue D ^a   Onate C ^a   Grau Lopez L ^b   Ramo Tello, C ^b   Pujol Borrell, R ^a   Martinez Caceres E ^a   Borràs, Francesc E ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; COLECALCIFEROL; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE;

ARTICLE; CD127LOW/NEGATIVE T CELL; CD25HIGH T CELL; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; FOXP3+ T CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PHENOTYPE; T LYMPHOCYTE; TOLEROGENIC DENDRITIC CELL; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SECRETION; TH1 CELL;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLECALCIFEROL; DENDRITIC CELLS; DEXAMETHASONE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; PHENOTYPE; SIROLIMUS; TH1 CELLS;

EID: 79958065289     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-89     Document Type: Article

References (80)

1. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immuno 2007, 7(9):665-77.
2. van Duivenvoorde LM, van Mierlo GJ, Boonman ZF, Toes RE. Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases. Immunobiology 2006, 211(6-8):627-32. 10.1016/j.imbio.2006.05.014, 16920501.
3. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007, 7(8):610-21. 10.1038/nri2132, 17627284.
4. Chuang JJ, Kleist C, Sandra-Petrescu F, Iancu M, Wang D, Opelz G, Terness P. Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum Immunol 2008, 69(3):p. 165-73.
5. van Kooten C, Lombardi G, Gelderman KA, Sagoo P, Buckland M, Lechler R, Cuturi MC. Dendritic Cells as a Tool to Induce Transplantation Tolerance: Obstacles and Opportunities. Transplantation 2011, 15(91(1)):2-7.
6. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008, 67(Suppl 3):90-6. iii.
7. Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 29(2):p. 156-83.
8. Torres-Aguilar H, Blank M, Jara LJ, Shoenfeld Y. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010, 10(1):8-17. 10.1016/j.autrev.2010.07.015, 20678591.
9. Torres-Aguilar H, Aguilar-Ruiz SR, González-Pérez G, Munguía R, Bajaña S, Meraz-Ríos MA, Sánchez-Torres C. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol 2010, 184(4):1765-75. 10.4049/jimmunol.0902133, 20083662.
10. Luther C, Adamopoulou E, Stoeckle C, Brucklacher-Waldert V, Rosenkranz D, Stoltze L, Lauer S, Poeschel S, Melms A, Tolosa E. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J Immunol 2009, 183(2):841-8. 10.4049/jimmunol.0802046, 19542375.
11. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010, 69(11):2042-50. 10.1136/ard.2009.126383, 3002758, 20551157.
12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-52. 10.1038/32588, 9521319.
13. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003, 196:125-46. 10.1046/j.1600-065X.2003.00079.x, 14617202.
14. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-96. 10.1146/annurev.iy.09.040191.001415, 1910679.
15. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711. 10.1146/annurev.immunol.21.120601.141040, 12615891.
16. Tatsumi T, Storkus WJ. Dendritic cell-based vaccines and therapies for cancer. Expert Opin Biol Ther 2002, 2(8):919-28. 10.1517/14712598.2.8.919, 12517270.
17. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10(5):475-80. 10.1038/nm1039, 15122249.
18. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33(4):464-78. 10.1016/j.immuni.2010.10.007, 21029958.
19. Palucka K, Ueno H, Fay J, Banchereau J. Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci 2009, 1174:88-98. 10.1111/j.1749-6632.2009.05000.x, 2759270, 19769741.
20. Peng JC, Thomas R, Nielsen LK. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 2005, 28(6):599-609. 10.1097/01.cji.0000175491.21099.04, 16224278.
21. Napoletano C, Pinto D, Bellati F, Taurino F, Rahimi H, Tomao F, Panici PB, Rughetti A, Frati L, Nuti M. A comparative analysis of serum and serum-free media for generation of clinical grade DCs. J Immunother 2007, 30(5):567-76. 10.1097/CJI.0b013e318046f396, 17589298.
22. D'Argenio DA, Wilson CB. A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design. Immunity 33(4):p. 437-40.
23. Germain RN. Vaccines and the future of human immunology. Immunity 2010, 33(4):441-50. 10.1016/j.immuni.2010.09.014, 21029956.
24. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004, 4(1):24-34. 10.1038/nri1256, 14704765.
25. Turnquist HR, Fischer RT, Thomson AW. Pharmacological modification of dendritic cells to promote their tolerogenicity in transplantation. Methods Mol Biol 2010, 595:135-48. 10.1007/978-1-60761-421-0_8, 19941109.
26. Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J Immunol 2005, 174(11):7433-9.
27. Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J, Huang X, Garcia B, White D, Dutartre P, Jevnikar AM, Zhong R. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003, 170(3):1304-12.
28. Huang H, Dawicki W, Zhang X, Town J, Gordon JR. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3-effector T cells. J Immunol 2010, 185(9):5003-10. 10.4049/jimmunol.0903446, 20870943.
29. Hill M, Cuturi MC. Negative vaccination by tolerogenic dendritic cells in organ transplantation. Curr Opin Organ Transplant 2010,
30. Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum 2010, 62(12):3656-65. 10.1002/art.27756, 20862679.
31. Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah AM, Burns EJ, Weiner HL. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010, 107(48):20768-73. 10.1073/pnas.1009201107, 2996442, 21068375.
32. van Duivenvoorde LM, Louis-Plence P, Apparailly F, van der Voort EI, Huizinga TW, Jorgensen C, Toes RE. Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis Rheum 2004, 50(10):3354-64. 10.1002/art.20513, 15476255.
33. van Duivenvoorde LM, Han WG, Bakker AM, Louis-Plence P, Charbonnier LM, Apparailly F, van der Voort EI, Jorgensen C, Huizinga TW, Toes RE. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J Immunol 2007, 179(3):1506-15.
34. Martin E, Capini C, Duggan E, Lutzky VP, Stumbles P, Pettit AR, O'Sullivan B, Thomas R. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum 2007, 56(7):2255-66. 10.1002/art.22655, 17599748.
35. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 2003, 987:258-61. 10.1111/j.1749-6632.2003.tb06057.x, 12727648.
36. Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J, Ampudia R, Verdaguer J, Pujol-Borrell R, Borràs FE, Vives-Pi M. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol 2010, 160(2):207-14. 2857943, 20030670.
37. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001, 7(7):761-5. 10.1038/89863, 11433329.
38. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004, 5(1):7-10.
39. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy?. Nat Rev Immunol 2007, 7(8):650-4. 10.1038/nri2137, 17653127.
40. Rescigno M. Dendritic cells in tolerance induction for the treatment of autoimmune diseases. Eur J Immunol 2010, 40(8):2119-23. 10.1002/eji.201040474, 20853497.
41. Steinman RM. Some active areas of DC research and their medical potential. Eur J Immunol 2010, 40(8):2085-8. 10.1002/eji.201040733, 20853490.
42. Soldevila B, Alonso N, Martínez-Arconada MJ, Morillas RM, Planas R, Sanmartí AM, Martínez-Cáceres EM. A prospective study of T-and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment. J Viral Hepat 2010,
43. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108(5):1435-40. 10.1182/blood-2006-03-006403, 16684955.
44. Adorini L, Penna G. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb Exp Pharmacol 2009, (188):251-73.
45. van Kooten C, Stax AS, Woltman AM, Gelderman KA. Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCs. Handb Exp Pharmacol 2009, (188):233-49.
46. Fischer R, Turnquist HR, Taner T, Thomson AW. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol 2009, (188):215-32.
47. Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, Robinson JH, Isaacs JD, Hilkens CM. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009, 85(2):243-50. 10.1189/jlb.0608374, 2700018, 18971286.
48. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164(5):2405-11.
49. Fazekasova H, Golshayan D, Read J, Tsallios A, Tsang JY, Dorling A, George AJ, Lechler RI, Lombardi G, Mirenda V. Regulation of rat and human T-cell immune response by pharmacologically modified dendritic cells. Transplantation 2009, 87(11):1617-28. 10.1097/TP.0b013e3181a5504c, 19502952.
50. Woltman AM, van der Kooij SW, de Fijter JW, van Kooten C. Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations. Am J Transplant 2006, 6(11):2580-91. 10.1111/j.1600-6143.2006.01520.x, 16952295.
51. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, Thomson AW. Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101(11):4457-63. 10.1182/blood-2002-11-3370, 12531798.
52. Steinbrink K, Wölfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997, 159(10):4772-80.
53. Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Hörl WH, Säemann MD, Weichhart T. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010, 185(7):3919-31. 10.4049/jimmunol.1000296, 20805416.
54. Karimi MH, Ebadi P, Pourfathollah AA, Moazzeni M, Soheili ZS, Samiee S. Comparison of Three Techniques for Generation of Tolerogenic Dendritic Cells: siRNA, Oligonucleotide Antisense, and Antibody Blocking. Hybridoma (Larchmt) 2010, 29(6):473-80. 10.1089/hyb.2010.0060, 21087095.
55. Svajger U, Obermajer N, Jeras M. Novel findings in drug-induced dendritic cell tolerogenicity. Int Rev Immunol 2010, 29(6):574-607. 10.3109/08830185.2010.522280, 21073328.
56. Xiao BG, Huang YM, Link H. Tolerogenic dendritic cells: the ins and outs of outcome. J Immunother 2006, 29(5):465-71. 10.1097/01.cji.0000210387.55951.8b, 16971802.
57. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol 2010, 11(8):647-55. 10.1038/ni.1894, 20644570.
58. Xia CQ, Peng R, Beato F, Clare-Salzler MJ. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol 2005, 62(1):45-54. 10.1111/j.1365-3083.2005.01640.x, 16091124.
59. Xing N, L Maldonado ML, Bachman LA, McKean DJ, Kumar R, Griffin MD. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002, 297(3):645-52. 10.1016/S0006-291X(02)02262-3, 12270143.
60. Griffin MD, Xing N, Kumar R. Gene expression profiles in dendritic cells conditioned by 1alpha,25-dihydroxyvitamin D3 analog. J Steroid Biochem Mol Biol 2004, 89-90(1-5):443-8.
61. Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003, 75(1):137-45. 10.1097/00007890-200301150-00025, 12544886.
62. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001, 22(7):394-400. 10.1016/S1471-4906(01)01952-4, 11429324.
63. Kubsch S, Graulich E, Knop J, Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2-and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur J Immunol 2003, 33(7):1988-97. 10.1002/eji.200323600, 12884865.
64. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105(12):4743-8. 10.1182/blood-2004-10-3932, 15746082.
65. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010, 108:111-65. 3050492, 21056730.
66. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002, 99(7):2468-76. 10.1182/blood.V99.7.2468, 11895781.
67. Cobbold SP, Adams E, Nolan KF, Regateiro FS, Waldmann H. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol Rev 2010, 236:203-18. 10.1111/j.1600-065X.2010.00913.x, 20636819.
68. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010, 236:219-42. 10.1111/j.1600-065X.2010.00923.x, 2919275, 20636820.
69. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101(5):455-8. 10.1016/S0092-8674(00)80856-9, 10850488.
70. Shevach EM, McHugh RS, Thornton AM, Piccirillo C, Natarajan K, Margulies DH. Control of autoimmunity by regulatory T cells. Adv Exp Med Biol 2001, 490:21-32. 10.1007/978-1-4615-1243-1_3, 11505971.
71. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001, 2(9):816-22. 10.1038/ni0901-816, 11526392.
72. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203(7):1701-11. 10.1084/jem.20060772, 2118339, 16818678.
73. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10(7):490-500. 10.1038/nri2785, 20559327.
74. Simonetta F, Chiali A, Cordier C, Urrutia A, Girault I, Bloquet S, Tanchot C, Bourgeois C. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immuno 2010, 40(9):2528-38.
75. Kang J, Huddleston SJ, Fraser JM, Khoruts A. De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol 2008, 83(5):1230-9. 10.1189/jlb.1207851, 18270248.
76. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004, 172(7):4100-10.
77. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, Adorini L. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005, 106(10):3490-7. 10.1182/blood-2005-05-2044, 16030186.
78. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001, 182:68-79. 10.1034/j.1600-065X.2001.1820105.x, 11722624.
79. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50. 10.1111/j.0105-2896.2006.00420.x, 16903904.
80. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001, 182:207-14. 10.1034/j.1600-065X.2001.1820117.x, 11722636.